Hillary Clinton released a statement Wednesday calling the skyrocketing price of the EpiPen “the latest troubling example of a company taking advantage of its consumers.”
EpiPen auto-injectors are life-saving devices for people who have severe allergies that could lead to anaphylactic shock. While the drug contained in EpiPens is cheap, the device itself, which is designed to be user-friendly and immediately dispense the correct dosage of the drug, is exorbitantly expensive.
“Over the last several years, Mylan Pharmaceuticals has increased the price of EpiPens by more than 400%,” Clinton noted in the statement. “They’re now charging up to $600 for a two-EpiPen set that must be replaced every 12-18 months. This both increases out-of-pocket costs for families and first responders, and contributes to higher premiums for all Americans and their employers.”
The statement called the price hikes “outrageous.”
“I believe that our pharmaceutical and biotech industries can be an incredible source of American innovation, giving us revolutionary treatments for debilitating diseases,” Clinton said. “But it’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them.”
Clinton called on Mylan to “immediately reduce the price of EpiPens” and noted her plan to require pharmaceutical manufacturers to “prove that any additional costs are linked to additional patient benefits and better value.” Clinton said there was “no apparent justification” for the high price of EpiPens.
Full Content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI